Desmopressin Suppresses Gonadotropin-Induced Spermatogenesis in Patients With Pituitary Stalk Interruption Syndrome: A Retrospective, Single-Center Cohort Study.

Ji Wen, Mao Jiangfeng, Nie Min, Wang Xi, Li Shuying, Yu Bingqing, Zhang Rui, Gao Yinjie, Huang Qibin, Wu Xueyan

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2021 Feb

filter terms:

To explore the influence of desmopressin on gonadotropin-induced spermatogenesis in patients with pituitary stalk interruption syndrome (PSIS). A single-center retrospective cohort study was conducted. All patients with PSIS had both gonadotropin and growth hormone (GH) deficiency. Patients were divided into desmopressin and nondesmopressin groups. The desmopressin and nondesmopressin groups were defined by the presence or absence of central diabetes insipidus, which determined whether the patient received desmopressin or not. The average age of gonadotropin therapy was 24.3 and 26.1 in the desmopressin and nondesmopressin groups, respectively. The rate of successful spermatogenesis in the 2 groups was 31.58% and 77.27%, respectively. The period for first sperm appearance was 13.62 ± 5.95 and 13.48 ± 6.69 months, respectively. A multivariable Cox proportional hazards model found that the adjusted hazard ratio for desmopressin was 0.260, indicating a "possible" detrimental effect of desmopressin on spermatogenesis. Central diabetes insipidus would be expected to show a similar detrimental effect. The spermatogenesis rate decreased with increased dosage of desmopressin. In the nondesmopressin group, the rate of spermatogenesis was similar between the GH group and the non-GH subgroup. The GH group had higher sperm count and concentration than the non-GH group. A minority of patients with PSIS had mild diabetes insipidus and received desmopressin therapy. The spermatogenesis rate decreased with increasing desmopressin dosage. In addition, GH supplementation did not affect the spermatogenesis rate. Copyright © 2020 AACE. Published by Elsevier Inc. All rights reserved.

Citation

Ji Wen, Mao Jiangfeng, Nie Min, Wang Xi, Li Shuying, Yu Bingqing, Zhang Rui, Gao Yinjie, Huang Qibin, Wu Xueyan. Desmopressin Suppresses Gonadotropin-Induced Spermatogenesis in Patients With Pituitary Stalk Interruption Syndrome: A Retrospective, Single-Center Cohort Study. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2021 Feb;27(2):124-130